Cancer cells survive therapy by dynamically rewiring their metabolism in response to nutrient availability, ...

JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials. This is an ASCO Meeting ...

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients ...

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and ...

Despite progress in cancer biology, deciphering the spatial architecture of the tumor microenvironment remains a challenge. Traditional approaches lack the resolution to map cell-type-specific gene ...

Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to ...

"Using 2 complementary methods, we demonstrated that T cells in the lung tumor microenvironment do, in fact, demonstrate evidence of poor immune function." — Brinda Emu, MD, Yale University School of ...

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its high prevalence, it has received far less molecular attention than colorectal ...

Pancreatic cancer cells are known for being hard to treat, partly because they change the environment around them to block drugs and immune cells. Scientists discovered that these tumors use a ...